Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

rtain

investments.

(6) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(7) To exclude the DoD Tricare program reversal as a result of the U.S.

Court of Appeals September 2006 ruling.

(8) To exclude charges associated with the settlement of the PROVIGIL

patent litigation ($6.0 million) and employee severance costs

associated with the European integration and restructuring ($4.0

million).

(9) To exclude charges related to the impairment of an intangible asset.

(10) To exclude the write-off of deferred debt issuance costs related to

the Zero Coupon convertible subordinated notes.

(11) Amounts shown no longer exclude the impact of SFAS 123(R). The

earnings press release issued on November 2, 2006 reflected

adjustments of $11.6 million in each of Research and development and

Selling, general and administrative expenses and $8.8 million in

Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

"ADJUSTED" CONSOLIDATED SALES DETAIL *

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $202,202 $14,904 $217,106

GABITRIL 12,952 881 13,833

CNS 215,154 15,785 230,939

ACTIQ
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014 ... ) announced today that Medtronic, Inc. (NYSE: ... application to the U.S. Food and Drug Administration ... II implantable drug infusion system (including a ... Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ... estimates and forecasts of the revenue and share ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... want to start a business? And it's going to be ... usually comes first. Is it Biotech? Software? Before raising any ... this commercial idea is critical because it is most likely ... is this? Patentable? Copyrightable? Trade Secret? Can it be identified ...
... awarded two federal grants totaling more than $800,000 for ... biotechnology company, which develops high throughput screening tools for ... I and Phase II Small Business Innovation Research ... conduct millions of biochemical, genetic, or pharmacological tests in ...
... Wisconsin-Madison 's partnership with Google to digitize ... make one of the best historical collections in the ... months, the popular search engine company, in collaboration with ... will make books and rare documents currently available only ...
Cached Biology Technology:Starting a tech business? Step 1 is minding the intellectual property 2Starting a tech business? Step 1 is minding the intellectual property 3Grants worth $800,000 help BellBrook Labs develop products 2Google to place Wisconsin history online 2Google to place Wisconsin history online 3Google to place Wisconsin history online 4
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... running out of room to maneuver. As forests in ... human uses, populations of these arboreal leaf eaters, which depend ... isolated and at risk. But one type of sustainable agriculture, ... critical refuges and bridges between intact forests for the iconic ...
... lives in increasingly humanised landscapes, with limited food resources ... to Spanish researchers, food availability plays a secondary role ... allow wolves to remain in human-dominated environments in Galicia. ... lupus signatus ) varies greatly across the Iberian Peninsula ...
... July 11, 2012 Researchers at the Translational Genomics Research ... could lead to a less costly, less invasive and more ... CKD is a major complication of diabetes, high blood pressure ... is characterized by a progressive deterioration of the kidney,s ability ...
Cached Biology News:Down on the cacao farm: Sloths thrive at chocolate's source 2Down on the cacao farm: Sloths thrive at chocolate's source 3The Iberian wolf lives close to humans more for refuge than for prey 2TGen method isolates biospecimens for treatment of kidney disease 2
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... is a recombinant Moloney murine leukemia ... Transcriptase is similar to MuLV reverse ... usage. MuLV reverse transcriptase is a ... single-stranded RNA as a template in ...
... F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite ... in rabbits, monkeys and humans. 8-iso ... non-specific lipid peroxidation. In both humans ... converted primarily to metabolites having 2 ...
Biology Products: